XTX Topco Ltd Raises Stock Position in Kenvue Inc. (NYSE:KVUE)

XTX Topco Ltd grew its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 93.1% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 79,233 shares of the company's stock after purchasing an additional 38,193 shares during the quarter. XTX Topco Ltd's holdings in Kenvue were worth $1,833,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in KVUE. Kovitz Investment Group Partners LLC raised its holdings in Kenvue by 27.4% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 61,804 shares of the company's stock worth $1,430,000 after purchasing an additional 13,304 shares during the period. Voya Financial Advisors Inc. increased its position in Kenvue by 5.8% in the third quarter. Voya Financial Advisors Inc. now owns 21,784 shares of the company's stock worth $507,000 after buying an additional 1,196 shares in the last quarter. Wahed Invest LLC bought a new position in shares of Kenvue in the third quarter worth about $1,076,000. Wills Financial Group Inc. lifted its position in shares of Kenvue by 2.0% during the 3rd quarter. Wills Financial Group Inc. now owns 242,266 shares of the company's stock valued at $5,604,000 after buying an additional 4,808 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Kenvue by 16.8% during the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company's stock valued at $2,942,458,000 after acquiring an additional 18,283,473 shares during the period. Institutional investors own 97.64% of the company's stock.

Kenvue Price Performance

NYSE:KVUE traded down $0.29 during trading hours on Friday, reaching $22.84. The stock had a trading volume of 9,708,660 shares, compared to its average volume of 13,840,819. The company has a 50 day moving average price of $22.97 and a two-hundred day moving average price of $21.11. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The stock has a market capitalization of $43.79 billion, a PE ratio of 41.53, a PEG ratio of 2.10 and a beta of 1.36. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same period in the previous year, the firm posted $0.31 EPS. The business's quarterly revenue was down .4% on a year-over-year basis. As a group, sell-side analysts anticipate that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.59%. The ex-dividend date was Wednesday, November 13th. Kenvue's dividend payout ratio (DPR) is 149.09%.

Analysts Set New Price Targets

A number of research firms have commented on KVUE. Piper Sandler raised their target price on shares of Kenvue from $20.00 to $21.00 and gave the stock a "neutral" rating in a research note on Monday, September 23rd. Jefferies Financial Group started coverage on shares of Kenvue in a research note on Tuesday, September 24th. They set a "buy" rating and a $27.00 target price on the stock. Royal Bank of Canada downgraded shares of Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 target price for the company. in a report on Tuesday, September 24th. Bank of America raised their price target on Kenvue from $24.00 to $27.00 and gave the company a "buy" rating in a report on Tuesday, October 22nd. Finally, JPMorgan Chase & Co. upped their price objective on Kenvue from $24.00 to $25.00 and gave the stock an "overweight" rating in a research note on Friday, October 11th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.